6 results
To confirm previous study results using a Solace Balloon and to support future marketing efforts in the European Union and provide data for publications.
The primary efficacy objective for this study was to evaluate the efficacy of gantenerumab compared with placebo administered to patients by subcutaneous (SC) injection over 100 weeks as measured by the following co-primary endpoints (final outcome…
The aim of the study is to document changes in CTO vessels physiology post PCI and at 3 months follow up. We intend to look for correlations between anatomical features identified with intravascular imaging and physiological parameters, how these…
This study will evaluate the efficacy and safety of gantenerumab compared with placebo in patients with early (prodromal to mild) Alzheimer's disease (AD).
The main objective of this study is to continue to collect long-term safety and tolerabilitydata in participants with AD treated with gantenerumab. Specific objectives andcorresponding endpoints for the study are outlined in Table 1 of the protocol
The primary objective for this study is to evaluate the safety, tolerability and efficacy of long-term gantenerumab administered by SC injection.